Registration for a live webinar on 'The role of T cells in COVID from asymptomatic to severe outcomes' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Function of important examples of PTK receptor families
-
1. The molecular basis of insulin action
- Prof. Morris White
-
2. The Eph receptor family
- Prof. Elena Pasquale
- Structure of PTK receptors and regulation of their kinases
-
3. EGF receptor family: targets for improving cancer therapy
- Prof. Tony Burgess
- Intracellular signal transduction by PTK receptors
-
4. PI 3-kinases and lipid messengers
- Prof. Bart Vanhaesebroeck
-
5. RTKs activate the ERK 1/2 MAPK cascade
- Prof. Melanie H. Cobb
-
6. The ERK1/2 MAPK cascade
- Prof. Melanie H. Cobb
- Archived Lectures *These may not cover the latest advances in the field
-
7. Receptor tyrosine kinases - function, families and evolution
- Prof. Tony Hunter
-
9. How the PDGF receptor induces cell proliferation
- Dr. Andrius Kazlauskas
-
10. VEGF inhibitors for anti-angiogenic therapy
- Prof. Kari Alitalo
-
12. Activation of PTK receptors in solid human tumors
- Dr. Marco Pierotti
-
14. SH2-containing PTPs (Shps) in RTK signaling and disease
- Prof. Benjamin G. Neel
-
16. Phospholipase C Gamma
- Prof. Graham Carpenter
- Ms. Cornelia Crooke
-
17. Imatinib as a paradigm of targeted cancer therapies
- Prof. Brian Druker
-
18. EGFR targeted therapies in lung cancer
- Dr. Pasi Janne
-
19. The VEGF family
- Prof. Kari Alitalo
-
20. The HGF receptor, a targettable regulator of invasive growth
- Prof. Paolo Comoglio
-
21. Structural biology of FGF signaling in human development and disease
- Dr. Moosa Mohammadi
-
22. EGF receptor family: targets for cancer therapeutics
- Prof. Tony Burgess
Printable Handouts
Navigable Slide Index
- Introduction
- Angiogenesis-VEGF
- Angiogenesis-VEGF-C/D
- VEGF and VEGFR tyrosine kinase
- Strategies to inhibition of VEGFR signaling
- MuMAb VEGF
- RhuMAb VEGF-Avastin
- Blocking Ab differ from other agents
- Anti-VEGF Ab prevents VEGF/VEGFR interaction
- Potential effects of inhibiting VEGF
- Anti-angiogenesis 'normalizes' tumour vasculature
- Anti-VEGF Ab modifies tumour vasculature
- VEGF inhibition can induce capillary regression
- Ranbizumab
- Pegaptabin
- 'Metronomic' anti-angiogenic chemotherapy
- Preclinical models
- Potential effects of anti-VEGF therapy
- Anti-VEGFR2 Mab
- Treatment of human xenograph tumors with DC101
- VEGFR-2 blockade
- VEGFR-2 block leads to increase in tumor hypoxia
- Anti-VEGFR-2 MAb and gemcitabine
- VEGFR-2 Ab IMC-1121b
- Structure and properties of VEGF trap
- Angiogenesis inhibitors in clinical trials
- Tumor lymphangiogenesis and metastasis
- VEGF - C/D trap prevents VEGFR-3 signaling
- VEGF - C/D trap prevents lymph vessels growth
- Inhibition of tumor lymphangiogenesis
- Blocking metastasis to lymph nodes
- Model of lymphatic metastasis
- Model of prevention of lymphatic metastasis
- Proteolytic processing of VEGF-C/D
- VEGF in hematogenous and lymphatic spread
- Conclusions (1)
- Conclusions (2)
Topics Covered
- Strategies to inhibit VEGFR signaling
- Potential effects of inhibiting VEGF
- Effects of anti-angiogenic therapy in preclinical models
- Treatment of Human Xenograft Tumors With DC101
- Combination Therapy with Anti-VEGFR-2 MAb and Gemcitabine
- Examples of angiogenesis inhibitors in clinical trials
- Inhibition of tumor lymphangiogenesis and lymph node metastasis with VEGFR-3-Fc
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Alitalo, K. (2007, October 1). VEGF inhibitors for anti-angiogenic therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 27, 2024, from https://hstalks.com/bs/912/.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Kari Alitalo has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.